// Company Overview //
| Stock Name | 雲頂新耀有限公司 - B |
|---|---|
| Stock Code | 01952 |
| Company Full Name | 雲頂新耀有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，專注治療領域包括腫瘤、免疫學、心腎疾病及感染性疾病。 |
| Listing Date | 2020-10-09 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市南京西路1266號上海恒隆廣場辦公樓1號樓6601–6606室 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.everestmedicines.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Prospectus Date | 2020-09-25 |
|---|---|
| Offer Price | HK$ 55.00 / shares |
| Total Funds Raised | HK$ 1,747,570,000 |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 70.55 |
| First Day Change | 32.27% |
| First Day Volume | 42603100.0 |
| First Day Turnover | 3078790000.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、60%或約1,970.4百萬港元用于我們的四款支柱產品； 2、15%或約492.6百萬港元用于為我們管線中其他候選藥物的進行中及計劃臨床試驗、登記備案準備及潛在商業化提供資金； 3、15%或約492.6百萬港元用于為我們的業務發展活動及擴展藥品管線提供資金； 4、10%或約328.4百萬港元用作營運資金以及一般及行政用途。 |
|---|
// Underwriting Syndicate //
联席保荐人 (2)
高盛（亚洲）有限责任公司
Merrill Lynch (Asia Pacific) Limited
整体协调人 (5)
高盛（亚洲）有限责任公司
Merrill Lynch (Asia Pacific) Limited
花旗环球金融亚洲有限公司
中国国际金融香港证券有限公司
瑞士信贷(香港)有限公司
联席账簿管理人 (7)
高盛（亚洲）有限责任公司
Merrill Lynch (Asia Pacific) Limited
花旗环球金融亚洲有限公司
中国国际金融香港证券有限公司
瑞士信贷(香港)有限公司
野村国际(香港)有限公司
锦沄资产管理有限公司
联席牵头经办人 (7)
高盛（亚洲）有限责任公司
Merrill Lynch (Asia Pacific) Limited
花旗环球金融亚洲有限公司
中国国际金融香港证券有限公司
瑞士信贷(香港)有限公司
野村国际(香港)有限公司
锦沄资产管理有限公司
// Cornerstone Investors //
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | BlackRock Funds | 116,242,500 HKD | — | 3.33% | — | 6 months | 2021-04-09 |
| 2 | C-Bridge IV Investment Sixteen Limited | 232,485,000 HKD | — | 6.65% | — | 6 months | 2021-04-09 |
| 3 | Citadel Multi-Strategy Equities Master Fund Ltd. | 38,747,500 HKD | — | 1.11% | — | 6 months | 2021-04-09 |
| 4 | Cormorant Asset Management, LP | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 5 | GIC Private Limited | 154,990,000 HKD | — | 4.43% | — | 6 months | 2021-04-09 |
| 6 | Hillhouse Funds | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 7 | Indus Pacific Opportunities Master Fund, Ltd. | 38,747,500 HKD | — | 1.11% | — | 6 months | 2021-04-09 |
| 8 | Invus Public Equities, L.P. | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 9 | Janchor Partners Pan-Asian Master Fund | 232,485,000 HKD | — | 6.65% | — | 6 months | 2021-04-09 |
| 10 | Lake Bleu Prime Healthcare Master Fund Limited | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 11 | Octagon Investments Master Fund LP | 38,747,500 HKD | — | 1.11% | — | 6 months | 2021-04-09 |
| 12 | OrbiMed Funds | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 13 | RA Capital Healthcare Fund, L.P. | 348,727,500 HKD | — | 9.98% | — | 6 months | 2021-04-09 |
| 14 | Rock Springs Capital Master Fund LP | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 15 | Tybourne Equity Master Fund | 38,747,500 HKD | — | 1.11% | — | 6 months | 2021-04-09 |
| 16 | Woodline Master Fund LP | 38,747,500 HKD | — | 1.11% | — | 6 months | 2021-04-09 |
// Directors & Management //
| Chairman | 吳以芳 |
|---|---|
| Company Secretary | 劉綺華;楊景行 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 傅唯及關連人士(44.69%) |
|---|
